A Delaware federal judge on Monday blocked plaintiffs in a patent infringement suit against drugmaker Teva Pharmaceuticals USA from amending their complaint to reflect corrections made to a patent for a nasal spray.
U.S. District Chief Judge Leonard P. Stark of the District of Delaware said Meda Pharmaceuticals Inc. and Cipla Ltd. had dragged their feet in asking the court for leave to assert a certificate of correction in an amended complaint, and informal discussions to resolve the issue did not meet the good-cause requirement of showing diligence, he said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
